SLC5A2 and type 2 diabetes mellitus: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a promising group of new drugs for the treatment of T2D that act by preventing the reabsorption of glucose from the proximal renal tubule in the kidney [10].